Beta2-adrenergic Agonism and Muscle Remodelling

• Status: Recruiting
• Trial end date: 2021-05-30
• Target enrollment: 0
• Participant gender: All

Summary

The study aims to investigate gender-specific adaptations to beta2-adrenoceptor stimulation with selective short- and long-acting beta2-agonist with emphasis on skeletal muscle in relation to performance enhancing effects and anti-doping

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Morten Hostrup, PhD
• Treatments: Adrenergic Agents; Formoterol Fumarate; Terbutaline

Criteria

Inclusion Criteria:

• Healthy men and women, aged 18-45 years

• VO2max >55 ml/kg/min for men and >50 ml/kg/min for women (± biologic and techinical variation of 5.6% (Katch et al. 1982)

• Body Mass Index (BMI) < 26

Exclusion Criteria:

• Chronic user of beta2-agonist or allergy towards study drugs

• Serious adverse side effects of the used study drug

• Chronic disease that by the project physician would affect any of the outcomes of the study

• Smoker

• Chronic use of prescription medication (other than contraceptives for women)

• Pregnancy